Several analysts have recently updated their ratings and price targets for IMV (NYSE: IMV):

  • 6/12/2019 – IMV had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock. They wrote, “Valuation and risks to price target achievement. We reiterate our Buy rating and $11.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunities in the U.S. for only DPX-Survivac, the leading asset, in ovarian cancer (approximately 43% valuation contribution, 30% chance of success), DLBCL (15% valuation contribution, 15% chance of success), and the indications in the basket trial (41% valuation contribution, 10% chance of success).””
  • 6/4/2019 – IMV had its “buy” rating reaffirmed by analysts at Echelon Wealth Partners.
  • 6/3/2019 – IMV was given a new $10.00 price target on by analysts at Raymond James. They now have an “outperform” rating on the stock.
  • 6/3/2019 – IMV had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock. They wrote, “Valuation and risks to price target achievement. We reiterate our Buy rating and $11.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunities in the U.S. for only DPX-Survivac, the leading asset, in ovarian cancer (approximately 43% valuation contribution, 30% chance of success), DLBCL (15% valuation contribution, 15% chance of success), and the indications in the basket trial (41% valuation contribution, 10% chance of success).””
  • 5/29/2019 – IMV is now covered by analysts at B. Riley. They set a “buy” rating and a $11.00 price target on the stock.
  • 5/23/2019 – IMV was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “buy” rating. They now have a $4.25 price target on the stock. According to Zacks, “IMV Inc. is a clinical-stage immuno-oncology company. Its proprietary drug development platform provides a patented delivery formulation which enables controlled and prolonged exposure of antigens to the immune system. The company’s pipeline consists of DPX-Survivac, DPX-E7 and DPX-RSV which are in clinical stage. IMV Inc. is based in Halifax, Canada. “
  • 5/13/2019 – IMV was given a new $10.00 price target on by analysts at Raymond James. They now have a “market perform” rating on the stock.
  • 5/11/2019 – IMV was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “IMV Inc. is a clinical-stage immuno-oncology company. Its proprietary drug development platform provides a patented delivery formulation which enables controlled and prolonged exposure of antigens to the immune system. The company’s pipeline consists of DPX-Survivac, DPX-E7 and DPX-RSV which are in clinical stage. IMV Inc. is based in Halifax, Canada. “
  • 5/10/2019 – IMV was given a new $12.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.

IMV traded down $0.13 during trading on Wednesday, reaching $3.87. The stock had a trading volume of 1,522 shares, compared to its average volume of 29,239. Imv Inc has a 1-year low of $2.90 and a 1-year high of $7.07.

IMV (NYSE:IMV) last released its earnings results on Thursday, May 9th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $0.06 million during the quarter.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Morgan Stanley increased its holdings in shares of IMV by 565.3% in the first quarter. Morgan Stanley now owns 25,068 shares of the company’s stock valued at $101,000 after buying an additional 21,300 shares in the last quarter. FIL Ltd increased its holdings in shares of IMV by 6.6% in the first quarter. FIL Ltd now owns 2,862,000 shares of the company’s stock valued at $11,458,000 after buying an additional 177,000 shares in the last quarter. Ruffer LLP increased its holdings in shares of IMV by 10.6% in the first quarter. Ruffer LLP now owns 6,801,225 shares of the company’s stock valued at $27,313,000 after buying an additional 652,000 shares in the last quarter. Ironwood Investment Management LLC bought a new position in shares of IMV in the first quarter valued at $135,000. Finally, Hartford Financial Management Inc. increased its holdings in shares of IMV by 20.1% in the first quarter. Hartford Financial Management Inc. now owns 32,250 shares of the company’s stock valued at $129,000 after buying an additional 5,400 shares in the last quarter.

IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.

Further Reading: Cost of Capital

Receive News & Ratings for Imv Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imv Inc and related companies with MarketBeat.com's FREE daily email newsletter.